Frequently Asked Questions About NXGN.TA

What does Nextgen Biomed Ltd do?

Nextgen Biomed Ltd (NXGN.TA) operates in the Medical - Instruments & Supplies industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is NXGN.TA's market cap?

Nextgen Biomed Ltd (NXGN.TA) has a market capitalization of approximately $512.4 million, as of January 19, 2026, based on the most recent share price and shares outstanding.

Does NXGN.TA pay a dividend?

No — Nextgen Biomed Ltd (NXGN.TA) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is NXGN.TA profitable?

Nextgen Biomed Ltd (NXGN.TA) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

NXGN.TA (Nextgen Biomed Ltd) is no longer actively trading.

This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.

NXGN.TA

Nextgen Biomed Ltd

TLV·Medical, Instruments & Supplies · Healthcare

ILA 47.00ILA 2.00−4.08%

Market capILA 512.36M·Jan 19 3:24 PM UTC

Price Chart

ILA 47.00−ILA 2.00 (−4.08%)today

−97.88%CAGR −53.72%

Select date range

FromTo

Aug 12, 2002Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

NXGN.TA does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

Revenue₪0.00

Net Income−₪10.41M

Net Margin—

Operating Cash Flow−₪2.21M

Capital Expenditures₪28.04K

Free Cash Flow−₪2.24M

Return on Equity—

Return on Invested Capital28.0%

Net Debt₪2.49M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for NXGN.TA and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how NXGN.TA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NXGN.TA and 80,000+ other tickers.

About Nextgen Biomed Ltd

Nextgen Biomed Ltd focuses on developing external dermatological treatments for psoriasis. The company, which was established in 1990, originally operated under the name Sela Group.Com Ltd. before rebranding as Nextgen Biomed Ltd in February 2010. Its operations are headquartered in Tel Aviv, Israel.

CEO: Harel Hershtik
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Exchange: TLV
Employees: 3
Website: www.nextgen-biomed.com

Latest News

News Tab

No recent news available.

Frequently Asked Questions About NXGN.TA

What does Nextgen Biomed Ltd do?: Nextgen Biomed Ltd (NXGN.TA) operates in the Medical - Instruments & Supplies industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is NXGN.TA's market cap?: Nextgen Biomed Ltd (NXGN.TA) has a market capitalization of approximately $512.4 million, as of January 19, 2026, based on the most recent share price and shares outstanding.
Does NXGN.TA pay a dividend?: No — Nextgen Biomed Ltd (NXGN.TA) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is NXGN.TA profitable?: Nextgen Biomed Ltd (NXGN.TA) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.